Heron Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Heron Therapeutics

02/05/2025 14:46

Heron Therapeutics Inc HRTX.OQ HRTX.O is expected to show a rise in quarterly revenue when it reports  results on May 6 for the period ending March 31 2025

The Cary North Carolina-based  company is expected to report a 7.9% increase in revenue to $37.417 million from $34.67 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Heron Therapeutics Inc is for a loss of 1 cent per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00​, above​ its last closing price of $2.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.03
-0.03
0.02
Beat
175
Sep. 30 2024
-0.03
-0.03
-0.03
Met
10
Jun. 30 2024
-0.04
-0.04
-0.06
Missed
-50​
Mar. 31 2024
-0.08
-0.09
-0.02
Beat
77.8
​​Dec. 31 2023
-0.16
-0.16
-0.07
Beat
57.2
Sep. 30 2023
-0.29
-0.29
-0.17
Beat
41.9​
Jun. 30 2023
-0.23
-0.23
-0.35
Missed
-50
Mar. 31 2023
-0.21
-0.20
-0.27
Missed
-33

This summary was machine generated May 2 at 13:46 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)